Karlsson K, Nyberg F
Department of Pharmaceutical Biosciences, Uppsala University, Sweden.
J Chromatogr A. 2000 Sep 29;893(1):107-13. doi: 10.1016/s0021-9673(00)00758-5.
The new chromatographic system Akta-Purifier 10 (Amersham-Pharmacia Biotech), scaled for preparative HPLC, was used for the purification of Substance P (SP) endopeptidase activity in the ventral tegemental area (VTA) of the rat brain. SP endopeptidase previously identified and purified from human cerebrospinal fluid has been found to degrade the neuroactive peptide SP in a specific pattern. In this study we have recovered SP endopeptidase from the rat VTA following a purification scheme involving homogenization (ultrasonication) and extraction of the excised tissue, size-exclusion chromatography (Superdex 75 HR), and ion-exchange chromatography (Resource Q). In this way we were able to achieve a purification factor of almost 7,500, based on specific activity. The obtained SP endopeptidase activity, was then subjected to characterization with regard to inhibition profile. The enzyme activity was monitored by following the conversion of SP to its N-terminal fragment SP(1-7) using a radioimmunoassay, specific for the heptapeptide product. On basis of inhibition profile it was possible to discern two different SP endopeptidase-like activities, one sensitive toward the protease inhibitor phosphoramidon (preparation A), and another non-sensitive to phosphoramidon or captopril (preparation B). The molecular masses of preparations A and B, as derived from sodium dodecyl sulfate-polyacrylamide gel electrophoresis, were found to be 90,000 and 76,000, respectively. Our data suggest that the purified phosphoramidon sensitive endopeptidase activity may be an enzyme that plays a major role in the conversion of SP to its bioactive fragment SP(1-7) in the rat VTA. This is likely to be identical to the previously known neutral endopeptidase (EC 3.4.24.11). However, this study also demonstrates the existence of a distinct endopeptidase activity with properties in agreement with rat spinal cord SP endopeptidase. In the context of previously shown altered levels of SP(1-7) in the VTA during morphine withdrawal both purified enzyme activities may turn out to be responsible.
新型色谱系统Akta - Purifier 10(安玛西亚-Pharmacia生物技术公司),按制备型高效液相色谱进行了规模放大,用于纯化大鼠脑腹侧被盖区(VTA)中的P物质(SP)内肽酶活性。先前从人脑脊液中鉴定并纯化出的SP内肽酶,已发现其能以特定模式降解神经活性肽SP。在本研究中,我们按照包括匀浆(超声处理)和切除组织提取、尺寸排阻色谱(Superdex 75 HR)以及离子交换色谱(Resource Q)的纯化方案,从大鼠VTA中回收了SP内肽酶。通过这种方式,基于比活性我们能够实现近7500的纯化倍数。然后,对获得的SP内肽酶活性进行抑制谱方面的表征。使用对七肽产物特异的放射免疫分析法,通过追踪SP向其N端片段SP(1 - 7)的转化来监测酶活性。基于抑制谱,有可能辨别出两种不同的SP内肽酶样活性,一种对蛋白酶抑制剂磷酰胺素敏感(制剂A),另一种对磷酰胺素或卡托普利不敏感(制剂B)。通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳得出,制剂A和B的分子量分别为90,000和76,000。我们的数据表明,纯化的对磷酰胺素敏感的内肽酶活性可能是一种在大鼠VTA中对SP转化为其生物活性片段SP(1 - 7)起主要作用的酶。这可能与先前已知的中性内肽酶(EC 3.4.24.11)相同。然而,本研究也证明了存在一种具有与大鼠脊髓SP内肽酶特性相符的独特内肽酶活性。鉴于先前显示在吗啡戒断期间VTA中SP(1 - 7)水平发生改变,这两种纯化的酶活性可能都与之有关。